News

• Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
  13:30 - GlobeNewswire
•  
• Roche: Antibody cocktail reduces symptomatic COVID infections by 81%
  07:25 - TeleTrader
•  
• Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
  04/07/2021 / 15:00 - GlobeNewswire
•  
• Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
  04/01/2021 / 14:00 - GlobeNewswire
•  
• Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
  03/30/2021 / 13:30 - GlobeNewswire
•  
• Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
  03/18/2021 / 21:30 - GlobeNewswire
•  
• Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
  03/15/2021 / 07:00 - GlobeNewswire
•  
• FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
  03/04/2021 / 07:00 - GlobeNewswire
•  
• EMA extends use advice for Regeneron COVID mix
  02/26/2021 / 12:28 - TeleTrader
•  
• Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
  02/25/2021 / 22:05 - GlobeNewswire
•  
• Europe closes lower amid recovery uncertainties
  02/25/2021 / 17:31 - TeleTrader
•  
• Regeneron: COVID cocktail has clear efficacy
  02/25/2021 / 14:13 - TeleTrader
•  
• Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
  02/25/2021 / 13:30 - GlobeNewswire
•  
• Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
  02/24/2021 / 13:00 - GlobeNewswire
•  
• Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
  02/23/2021 / 14:00 - GlobeNewswire